Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Uterine Corpus Carcinoma: early-phase trial registry
A small indexed set (8 trials) with no open enrollment listed right now.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · none currently recruiting · #2,176 of 28,707 conditions by registered trial count
Recurrent Uterine Corpus Carcinoma: 8 US clinical trials tracked, none currently recruiting.
Recurrent Uterine Corpus Carcinoma is the subject of 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Gynecologic Oncology Group, running 4 of these trials.
Enrollment posture brief
Registry condition recurrent-uterine-corpus-carcinoma
OPEN 0 | RECR 0% | LATE 1 | EARLY 5 | RANK #2176 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Recurrent Uterine Corpus Carcinoma has no open enrollment in this registry pull (8 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Uterine Corpus Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Uterine Corpus Carcinoma is recruiting below its size-band peers.
0 of 8 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Uterine Corpus Carcinoma research.
Gynecologic Oncology Group accounts for 4 of 8 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Uterine Corpus Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 75 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.
-
Recurrent Uterine Corpus Carcinoma research is mostly interventional.
6 interventional and 2 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
8 total, page 1 of 1
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
NCT01970722
Prognostic Biomarkers in Patients With Endometrial Cancer
Gynecologic Oncology Group
NCT01208467
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
GOG Foundation
NCT00063999
Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Gynecologic Oncology Group
NCT01164735
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Gynecologic Oncology Group
NCT00064025
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
National Cancer Institute (NCI)
NCT01307631
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Gynecologic Oncology Group
NCT01225887
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
NCT00006089
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Uterine Corpus Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Uterine Corpus Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Uterine Corpus Carcinoma page
8 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Recurrent Uterine Corpus Carcinoma trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Gynecologic Oncology Group sponsors the most Recurrent Uterine Corpus Carcinoma trials on record, review their full trial history before evaluating a specific study. See Gynecologic Oncology Group's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Uterine Corpus Carcinoma condition card totals 8 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.